Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T14:25:34.869Z.
Calculation as of: 2026-10-06T14:25:34.869Z.
Quote observation: 2026-10-06T14:25:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 29544bddba9647c45f1d116a926e76fce0232fba061b4e126f75ac7ab8440d73
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$843.53M
Price/OCF Ratio
N/A
TTM Avg
10.75
3Y Avg
10.75
5Y Avg
10.75
Market Cap
$865.29M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$791.01M
Price/OCF Ratio
N/A
TTM Avg
422.02
3Y Avg
258.29
5Y Avg
228.94
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $835.01M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $843.53M | N/A | 10.75 | 10.75 | 10.75 |
| Alumis Inc. (ALMS)vs › | $825.62M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $818.83M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $817.92M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | N/A | 5.49 | 6.61 | 6.61 |
| InMode Ltd. (INMD)vs › | $808.81M | 9.13 | 9.81 | 9.87 | 15.02 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $865.29M | N/A | N/A | N/A | N/A |
| Gyre Therapeutics, Inc. (GYRE)vs › | $791.01M | N/A | 422.02 | 258.29 | 228.94 |
| AdaptHealth Corp. (AHCO)vs › | $793.88M | 1.36 | 2.23 | 2.49 | 4.68 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
